Skip to main content
Medical information Clinical review pending

Genetic Testing

Irnotecan Toxicity Assessment UGT1A1 Genotyping Gilbert Syndrome

This genetic test assesses your UGT1A1 gene to understand how your body processes Irnotecan chemotherapy, helping to predict potential toxicity and guide personalized treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube)
Results
Results are typically available within 7-8 days. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 15,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Irnotecan Toxicity Assessment UGT1A1 Genotyping Gilbert Syndrome test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients prescribed Irnotecan chemotherapy
  • ✓Individuals with a family history of Gilbert Syndrome
  • ✓Patients experiencing adverse reactions to Irnotecan
  • ✓Personal history of liver conditions potentially affecting drug metabolism
02

In plain language

What this test helps you understand

This test helps predict the risk of severe toxicity from Irnotecan chemotherapy by identifying genetic variations in the UGT1A1 gene. It enables clinicians to adjust Irnotecan dosage or consider alternative therapies to minimize adverse reactions and optimize treatment outcomes for patients with cancer.
The Irnotecan Toxicity Assessment UGT1A1 Genotyping Gilbert Syndrome test is a genetic analysis that looks at your UGT1A1 gene. This gene provides instructions for making an enzyme that helps break down Irnotecan, a chemotherapy drug often used for colorectal cancer. Understanding variations in this gene is crucial because it can affect how your body metabolizes Irnotecan, potentially leading to severe side effects. This test helps healthcare providers tailor Irnotecan therapy to minimize toxicity and improve treatment effectiveness. It is particularly relevant for individuals prescribed Irnotecan or those with a family history of Gilbert Syndrome, a condition related to the UGT1A1 gene's function. Knowing your genetic profile allows for more informed decisions about your cancer treatment plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube)
MethodologyDNA extraction followed by genetic analysis of the UGT1A1 gene using molecular techniques (e.g., PCR, sequencing). Confirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically assesses the UGT1A1 gene variations associated with Irnotecan metabolism. It does not predict all potential side effects or interactions with other medications. Other genetic and non-genetic factors can also influence drug response. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Irnotecan toxicity refers to the adverse side effects experienced by patients undergoing Irnotecan chemotherapy. These can range from mild to severe, including diarrhoea, nausea, vomiting, and bone marrow suppression. This test helps identify individuals at higher risk.
Gilbert Syndrome is a common, mild liver condition where the liver doesn't properly process bilirubin. It is often associated with variations in the UGT1A1 gene and can affect how the body metabolizes certain medications, including Irnotecan.
If the test shows genetic variations that increase your risk of Irnotecan toxicity, your doctor may adjust your dosage, monitor you more closely, or consider alternative treatment options.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
Yes, home sample collection services are available for your convenience. Please contact us to arrange.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp